Empowering Neuroscience Discovery
Reliable ELISA Kits, Antibodies, and Research Tools for the Study of Neurodegenerative Diseases and Schizophrenia
About Us
We are a trusted distributor of research-grade ELISA kits, antibodies, microscopy systems, and molecular biology reagents, supporting laboratories and researchers exploring neurodegenerative and psychiatric diseases.
Our goal is to make high-quality reagents accessible to those investigating complex brain disorders from Alzheimer’s and Parkinson’s disease to schizophrenia and rare (orphan) neurological conditions.
By partnering with globally recognized manufacturers, we guarantee accuracy, reproducibility, and innovation for every product.
Chronic Neurodegenerative Diseases
Examples:
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- Amyotrophic lateral sclerosis (ALS)
- Other orphan neurodegenerative diseases (rare genetic types)
Learn more
1.Clinical Assessment
- Observation of symptoms such as memory loss, tremors, coordination problems, or muscle weakness.
- Neurological exams by specialists.
How They Are Detected:
2.Neuroimaging
- MRI or CT scans: Show structural brain changes (atrophy, lesions, degeneration).
- PET or SPECT scans: Detect abnormal brain metabolism or amyloid/tau protein deposits (especially in Alzheimer’s).
- Cerebrospinal fluid (CSF) analysis: Detects abnormal levels of proteins like β-amyloid, tau, or α-synuclein.
- Blood biomarkers (recent advances): Detect neurofilament light chain (NfL) or phosphorylated tau for early diagnosis.
4.Genetic Testing
- Used for inherited or orphan neurodegenerative diseases.
- Identifies mutations in specific genes.
Schizophrenia
This is a psychiatric disorder, not neurodegenerative in the classical sense, but it involves brain structure and neurotransmitter abnormalities.
How It Is Detected:
01
Clinical Diagnosis
- Based on symptoms (delusions, hallucinations, disorganized speech/behavior, negative symptoms).
- Diagnostic manuals: DSM-5 or ICD-11 criteria.
- Psychiatric interview and patient history are essential.
02
Neuroimaging (supportive, not diagnostic)
- MRI or fMRI may show altered brain connectivity or reduced gray matter volume in some brain regions.
03
Neurochemical and Genetic Studies
- Research identifies dopamine/glutamate pathway alterations.
- Polygenic risk scores and family history can indicate higher susceptibility.
Our latest content
Check out what's new in our company !
Why Choose Us
- High-quality, validated reagents
- Competitive pricing and bulk discounts
- Fast worldwide shipping
- Partnership with certified manufacturers
- Dedicated scientific support



